Study Finds Tirzepatide Triggers 5.44% Hair Loss Rate vs 3.63% for Semaglutide
Updated
Updated · Women's Health · Aug 18
Study Finds Tirzepatide Triggers 5.44% Hair Loss Rate vs 3.63% for Semaglutide
3 articles · Updated · Women's Health · Aug 18
Summary
Among 8,985 female patients, new alopecia cases were recorded in 5.44% of tirzepatide users versus 3.63% of semaglutide users in a preprint observational study.
Health records from a 30 million-patient network showed the gap emerging by six months—1.55% versus 1.24%—and widening by 12 months to 4.20% versus 2.88%.
Matched analyses still found more hair loss with tirzepatide even when patients lost similar weight, suggesting weight loss alone may not explain the difference.
Doctors said much shedding may reflect temporary telogen effluvium, but persistent shedding, bald patches, scalp pain or scarring should be evaluated by a dermatologist.
The findings remain preliminary because the study has not been peer reviewed, even as U.S. GLP-1 weight-loss use rose from 3% in 2024 to 11% in 2026.